571.7

+1.88%↑

FDX

359

+0.77%↑

CTAS

172.06

+1.74%↑

HEICO

275.29

+0.56%↑

PAYX

90.85

-1.35%↓

571.7

+1.88%↑

FDX

359

+0.77%↑

CTAS

172.06

+1.74%↑

HEICO

275.29

+0.56%↑

PAYX

90.85

-1.35%↓

571.7

+1.88%↑

FDX

359

+0.77%↑

CTAS

172.06

+1.74%↑

HEICO

275.29

+0.56%↑

PAYX

90.85

-1.35%↓

571.7

+1.88%↑

FDX

359

+0.77%↑

CTAS

172.06

+1.74%↑

HEICO

275.29

+0.56%↑

PAYX

90.85

-1.35%↓

571.7

+1.88%↑

FDX

359

+0.77%↑

CTAS

172.06

+1.74%↑

HEICO

275.29

+0.56%↑

PAYX

90.85

-1.35%↓

Home・Akciju saraksts・Cross Country Healthcare Inc

Cross Country Healthcare Inc

Slēgts

SektorsRūpniecība

9.33 -0.85

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

9.23

Max

9.52

Galvenie mērījumi
By Trading Economics
Ienākumi	-78M -83M
Pārdošana	-13M 237M
Peļņas marža	-35.026
Darbinieki	7,890
EBITDA	12M 11M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+37.28% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	21M 310M
Iepriekšējā atvēršanas cena	10.18
Iepriekšējā slēgšanas cena	9.33

Ziņu noskaņojums

By Acuity

19%

81%

36 / 405 Rangs Industrials

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bullish Evidence

13.52 / 13.92 Atbalsts un pretestība

Cross Country Healthcare Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 31. marts 23:31 UTC

Karstas akcijas

Stocks to Watch: Nike, RH, NCino

2026. g. 31. marts 22:35 UTC

Peļņas

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

2026. g. 1. apr. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

2026. g. 31. marts 23:50 UTC

Iegādes, apvienošanās, pārņemšana

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

2026. g. 31. marts 23:43 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

2026. g. 31. marts 23:33 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

2026. g. 31. marts 23:21 UTC

Peļņas

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

2026. g. 31. marts 23:14 UTC

Tirgus saruna

Peļņas

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

2026. g. 31. marts 23:12 UTC

Tirgus saruna

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke 2025 Loss Widens >000002.SZ

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

2026. g. 31. marts 21:46 UTC

Iegādes, apvienošanās, pārņemšana

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

2026. g. 31. marts 21:36 UTC

Tirgus saruna

West African Resources's Costs Higher Than Bull Expected -- Market Talk

2026. g. 31. marts 21:35 UTC

Peļņas

Nike Expects China Sales Down 20% in 4Q, CFO Says

2026. g. 31. marts 21:35 UTC

Peļņas

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

2026. g. 31. marts 21:35 UTC

Peļņas

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

2026. g. 31. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

2026. g. 31. marts 21:33 UTC

Peļņas

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

2026. g. 31. marts 21:32 UTC

Peļņas

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

2026. g. 31. marts 21:28 UTC

Peļņas

Nike Expects to End 4Q With Elevated Inventory, CFO Says

2026. g. 31. marts 21:26 UTC

Peļņas

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

2026. g. 31. marts 21:25 UTC

Peļņas

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

2026. g. 31. marts 21:24 UTC

Tirgus saruna

Peļņas

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

2026. g. 31. marts 21:22 UTC

Peļņas

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

2026. g. 31. marts 21:22 UTC

Peļņas

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

2026. g. 31. marts 21:21 UTC

Peļņas

Nike's Digital Channel Still Too Promotional, CFO Says

2026. g. 31. marts 21:20 UTC

Peļņas

Nike CEO: Converse Remains Important to Portfolio

Salīdzinājums

Cenas izmaiņa

Cross Country Healthcare Inc Prognoze

Cenas mērķis

By TipRanks

37.28% augšup

Prognoze 12 mēnešiem

Vidējais 13 USD 37.28%

Augstākais 15 USD

Zemākais 10 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cross Country Healthcare Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Cross Country Healthcare Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

13.52 / 13.92Atbalsts un pretestība

Recent bullish events outweigh bearish events.

All events are bearish.

Recent bearish events outweigh bullish events.

Noskaņojums

By Acuity

36 / 405 Rangs Rūpniecība

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Cross Country Healthcare Inc

Cross Country Healthcare, Inc. provides talent management and other consultative services for healthcare clients in the United States. The company's Nurse and Allied Staffing segment provides traditional staffing, recruiting, and value-added total talent solutions, including temporary and permanent placement of travel and local nurse and, allied professionals; temporary placement of healthcare leaders within nursing, allied, physician, and human resources; vendor neutral and managed services programs; education healthcare services; in-home care services; and outsourcing services. It also offers staffing solutions for registered nurses, licensed practical nurses, certified nurse assistants, practitioners, pharmacists, and other allied professionals on per diem and short-term assignments; and clinical and non-clinical professionals on long-term contract assignments, as well as workforce solutions, including MSP, VMS, in- home care, education healthcare, RPO, project management, and other outsourcing and consultative services. This segment provides retained search services for healthcare professionals, as well as contingent search and recruitment process outsourcing services. It serves public and private acute care and non-acute care hospitals, government facilities, local and national healthcare plans, managed care providers, public and charter schools, outpatient clinics, ambulatory care facilities, physician practice groups, and other healthcare providers under the Cross Country brand. Its Physician Staffing segment provides physicians in various specialties, certified registered nurse anesthetists, nurse practitioners, and physician assistants under the Cross Country Locums brand on temporary assignments. It serves various healthcare facilities, such as acute and non-acute care facilities, medical group practices, government facilities, and managed care organizations. The company was founded in 1986 and is headquartered in Boca Raton, Florida.